HUP0100105A2 - TNF-antagonisták alkalmazása szeptikus betegségek kezelésére szolgáló gyógyszerként - Google Patents

TNF-antagonisták alkalmazása szeptikus betegségek kezelésére szolgáló gyógyszerként

Info

Publication number
HUP0100105A2
HUP0100105A2 HU0100105A HUP0100105A HUP0100105A2 HU P0100105 A2 HUP0100105 A2 HU P0100105A2 HU 0100105 A HU0100105 A HU 0100105A HU P0100105 A HUP0100105 A HU P0100105A HU P0100105 A2 HUP0100105 A2 HU P0100105A2
Authority
HU
Hungary
Prior art keywords
medicaments
application
tnf antagonists
treating septic
septic diseases
Prior art date
Application number
HU0100105A
Other languages
English (en)
Inventor
Lothar Daum
Jürgen Eiselstein
Martin Kaul
Joachim Kempeni
Hartmut Kupper
Original Assignee
Knoll Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Aktiengesellschaft filed Critical Knoll Aktiengesellschaft
Publication of HUP0100105A2 publication Critical patent/HUP0100105A2/hu
Publication of HUP0100105A3 publication Critical patent/HUP0100105A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány TNF-antagonisták alkalmazására vonatkozik,olyan szeptikus megbetegedések kezelésére szolgáló gyógyszerelőállításához, amelyeket az interleukin-6 szérumszint növekedésejellemez legalább harminc perces mérési időközben. Ó
HU0100105A 1997-10-23 1998-10-15 Application of tnf antagonists as medicaments for treating septic diseases HUP0100105A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19746868A DE19746868A1 (de) 1997-10-23 1997-10-23 Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
PCT/EP1998/006545 WO1999021582A2 (de) 1997-10-23 1998-10-15 Verwendung von tnf-antagonisten als arzneimittel zur behandlung von septischen erkrankungen

Publications (2)

Publication Number Publication Date
HUP0100105A2 true HUP0100105A2 (hu) 2001-05-28
HUP0100105A3 HUP0100105A3 (en) 2003-08-28

Family

ID=7846420

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100105A HUP0100105A3 (en) 1997-10-23 1998-10-15 Application of tnf antagonists as medicaments for treating septic diseases

Country Status (13)

Country Link
EP (1) EP1024831A2 (hu)
JP (1) JP2001521009A (hu)
KR (1) KR20010024549A (hu)
CN (1) CN1163272C (hu)
AU (1) AU756167B2 (hu)
BR (1) BR9813114A (hu)
CA (1) CA2306790A1 (hu)
DE (1) DE19746868A1 (hu)
HU (1) HUP0100105A3 (hu)
IL (1) IL135083A0 (hu)
NO (1) NO20001894D0 (hu)
WO (1) WO1999021582A2 (hu)
ZA (1) ZA989615B (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76640C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
CZ2013105A3 (cs) 2010-07-15 2013-05-22 Iliich Epshtein@Oleg Zpusob zvýsení úcinku aktivované potencované formy protilátky
GB2496794B (en) 2010-07-15 2017-11-01 Iliich Epshtein Oleg Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
ES2398646T3 (es) * 2010-07-24 2013-03-20 F. Hoffmann-La Roche Ag Estabilización de la interleuquina-6 en soluciones de suero

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626572B2 (en) * 1988-07-18 1992-08-06 Chiron Corporation Monoclonal antibodies reactive with cachectin
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above

Also Published As

Publication number Publication date
NO20001894L (no) 2000-04-12
CN1163272C (zh) 2004-08-25
DE19746868A1 (de) 1999-04-29
AU756167B2 (en) 2003-01-09
EP1024831A2 (de) 2000-08-09
CN1277556A (zh) 2000-12-20
IL135083A0 (en) 2001-05-20
CA2306790A1 (en) 1999-05-06
WO1999021582A3 (de) 1999-07-15
NO20001894D0 (no) 2000-04-12
HUP0100105A3 (en) 2003-08-28
BR9813114A (pt) 2000-08-15
ZA989615B (en) 2000-04-20
JP2001521009A (ja) 2001-11-06
WO1999021582A2 (de) 1999-05-06
AU1228499A (en) 1999-05-17
KR20010024549A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
FI963101A (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
HUP0102511A2 (hu) Kombinált gyógykezelés bipoláris betegségek kezelésére
ATE207349T1 (de) Thip zur behandlung von schlafstörungen
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
ATE318135T1 (de) Verwendung von dapoxetin, a selektiver serotonin- aufnahme inhibitor mit schnellem wirkungseintritt,zur behandlung von sexueller dysfunction
FR2760369B1 (fr) Stimulateur cardiaque multisites pour le traitement des insuffisances cardiaques par stimulation
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
HUP0100105A2 (hu) TNF-antagonisták alkalmazása szeptikus betegségek kezelésére szolgáló gyógyszerként
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
DE69819922D1 (de) 2-Amino-6-methyl-7-acetyl-tetralin und pharmazeutische Zusammensetzungen zur Vorbeugung und therapeutischen Behandlung von entzündlichen und/oder Autoimmunkrankheiten
HUP0103712A2 (hu) Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
PT1231908E (pt) Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia
DE60004473D1 (de) Verwendung von gaba-b rezeptor liganden zur herstellungen von medikamenten zur behandlung von neurodegenerativen erkrankungen
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
DE69521281T2 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
ATE262343T1 (de) Verwendung von gnrh analogen zur behandlung von schizophrenie
TR199801800T2 (xx) Uykusuzluk tedavisi.